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A B S T R A C T
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:
To determine the accuracy of simple measures of adherence, including patient self-report, tablet counts, pharmacy records, electronic
monitoring, or composite methods, for detecting non-suppressed viral load in people living with HIV.
B A C K G R O U N D
Target condition being diagnosed
Across all fields of medicine, low patient adherence is a barrier
to realising the benefits of medication (Nieuwlaat 2014), and is
associated with higher mortality (Simpson 2006).
The World Health Organization (WHO) recommends provision
of antiretroviral therapy (ART) to all people living with HIV,
regardless of CD4 count (WHO 2016). At an individual level,
ART reduces the risk of progression to AIDS or death, increases
the likelihood of immune recovery, and reduces the risk of sex-
ual transmission to seronegative partners. At a population level,
widespread ART may reduce HIV incidence and offers a tool to
end the HIV epidemic, as acknowledged within the Joint United
Nations Programme on HIV/AIDS (UNAIDS) 90:90:90 target
(UNAIDS 2014). This aims that by 2020, 90% of all people liv-
ing with HIV will know their HIV status, 90% of all people with
diagnosed HIV infection will receive sustained ART, and 90% of
all people receiving ART will have viral suppression.
With respect to HIV, for the individual and population level ben-
efits of ART to be realised, patient adherence is essential. Adher-
ence to ART is the primary determinant of viral suppression. In
one meta-analysis of observational studies, only 62% of people re-
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ceiving ART reported more than 90% adherence (Ortego 2011).
Poor adherence increases the risk of transmission, accumulation of
resistance mutations, disease progression, and death. Previous sys-
tematic reviews indicate a number of possible treatments for poor
adherence to ART, indicating the benefit of measuring adherence
(Horvath 2012; Kanters 2017; Rueda 2006).
One European Consensus document defines “adherence to med-
ications” as the process by which patients take their medication
as prescribed. This term describes multiple behaviours. (Vrijens
2012). There are four measurable subcategories of adherence to
medications. These include:
• initiation: when a patient takes the first dose of a
prescribed medication;
• implementation: the extent to which a patient’s actual
dosing corresponds to the prescribed dosing regimen, from
initiation until the last dose;
• persistence: the length of time between initiation and the
last dose;
• discontinuation: when a patient stops taking the
prescribed medication.
Initiation and discontinuation are discontinuous (stop/start) mea-
sures, whereas implementation is a continuous measure. This pre-
cludes a single useful quantitative parameter to cover all three.
Most research focuses on the implementation phase, that is: the
extent to which a patient’s actual dosing corresponds to the pre-
scribed dosing regimen. The implementation component can be
expressed via summary statistics which describe the implementa-
tion of a dosing regimen over a defined interval of time, for exam-
ple the proportion of days with the correct number of doses over
a given period.
Although the implementation phase of adherence exists within a
continuum from 0% to more than 100%, studies typically strat-
ify adherence into dichotomous variables of ‘adherence’ and ‘non-
adherence’. There are no specific consensus criteria for identifying
these dichotomous categories of ‘adherence’ and ‘non-adherence’.
Traditionally, across fields of medicine, trials consider rates of less
than 80% to represent non-adherence (Osterberg 2005). With re-
spect to HIV, where non-adherence risks resistance mutations, tri-
als have traditionally considered a threshold of greater than 95%
as optimal (Paterson 2000). In practice, the level of adherence
required to improve immune function and achieve viral suppres-
sion will vary by regimen and by prior history of viral suppression
(Haberer 2017). For example, people with a longer-term history
of viral suppression may be able to miss more doses without viral
rebound (Lima 2010). Indeed, adopting lower adherence thresh-
olds may not effect viral outcomes (Bezabhe 2016).
The definition of viral suppression is standard across guidelines, as
an HIV ribonucleic acid (RNA) level below the lower limit of de-
tection of available assays. However, the terminology for describ-
ing the absence of viral suppression is heterogeneous across the
literature, incorporating concepts such as viral failure, incomplete
response, viral rebound, viral blips, and low level viraemia. Table
1 summarises the varying definitions of viral failure used interna-
tionally. Of note, the WHO definition incorporates an adherence
support intervention before viral failure can be diagnosed.
Index test(s)
The index test will be measures of adherence that could be utilized
in resource-limited settings.
The WHO Guidelines on the use of antiretroviral drugs for treat-
ing and preventing HIV identify a need to “determine optimal
ways to proactively monitor adherence and identify through sim-
ple triage those patients in greatest need of adherence support”
(WHO 2016). The guideline document uses terms relating to
‘simple’ on 51 separate instances, but there is no standard defini-
tion. However, in context, this relates to a public health approach
which is “feasible on a large scale in resource-limited settings”,
with decentralization and integration of services, including task
shifting. With respect to ‘task shifting’, WHO recommends that
trained and supervised community health workers can dispense
ART between regular clinical visits (WHO 2016), and suggests
that these workers adopt responsibility for monitoring patient ad-
herence (WHO 2017).
In relation to these considerations, this review will focus on mea-
sures of adherence that could be used at the ‘community’ or ‘health
centre’ level as defined by a previous Cochrane review (Kredo
2014), in a nomenclature reproduced in Table 2. As such, the
measure:
• could be administered by trained volunteers, health
assistants, nurse aides, and community health workers with a
maximum of few months of training;
• would not require infrastructure such as laboratories which
are more commonly found at enhanced health centres or
hospitals.
This would not preclude use of the measure at higher levels of
care. The following measures of adherence behaviour could meet
these criteria:
• self-report;
• tablet counts;
• pharmacy records or secondary database analysis, or both;
• electronic monitoring;
• composite measures of the above.
We describe these further below.
Self-report
The term self-report involves a question, or set of questions, to
which a patient responds. The mode of administration may be
self-completion, or interviewer administered.Themediummaybe
paper or electronic. There is no consensus taxonomy for self-report
within the literature, but in broad terms, self-report questions may
include:
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• behavioural questions: questions asking patients to directly
relate their adherence behaviour. In turn, such questions may be:
◦ count based: a specific day-by-day enquiry regarding
missed doses. For example, how many doses did you miss yesterday?
The day before yesterday? Three days ago? (Chesney 2000);
◦ estimate based: asking people to estimate how they
took their treatment over a period of time. This might be based
around a visual analogue scale, for example, mark the point along
the line that most closely reflects how much of your HIV medications
you have taken in the last month? (Kabore 2015);
• attitudinal questions: these include questions asking
patients about knowledge and beliefs, for example:
◦ perceived barriers. Did you ever miss a dose due to
forgetfulness?
◦ health beliefs. Sometimes if you feel worse, do you stop
taking your medications? (Knobel 2002);
◦ self-efficacy. How confident are you that you can take
your medicines? (EACS 2017).
The extent to which attitudinal questions are a valid form of as-
sessment of adherence behaviour is unclear (Stirratt 2015), but
inclusion of such questions will not preclude a questionnaire from
this review. One previous systematic review covering all fields of
medicine identified that the number of questions in self-report
adherence measures ranged from one to 30, with a median of
eight (Nguyen 2014). It is unlikely that a 30-item questionnaire
could be termed ‘simple triage’, or be used by community health
workers. Therefore, this review will exclude self-report containing
more than eight questions, or which the review authors deem to
be prohibitively complex for use at this level.
Tablet counts
The provider counts the remaining tablets (or volume of liquid)
in previously dispensed bottles and calculates an adherence per-
centage. This is based on expected versus actual tablets taken over
a prescribed dispensing period. Counts may take place in clinic or
unannounced (in the form of telephone or home visits).
Pharmacy records or secondary database analysis, or
both
Providers can use dates of prescription refills to calculate adherence
measures. These can be broadly considered under three categories
(Lam 2015).
• Medication possession ratio (MPR): this measures the
time for which a person possesses a supply of each medication
class available, as a proportion of the time of eligibility for that
medication. These measures are most commonly calculated over
a three- to 12-month period but may be shorter or longer. We
consider that the variability in methods used to calculate MPR
will create challenges to meta-analysis. We will pool MPR data
and use subgroup analyses to investigate heterogeneity
introduced by different methods.
• Tablet pickup: whether a person picks up all or a majority
of their prescribed ARVs, categorizing people into either
adherent or non-adherent based on a specified criteria.
• Continuous measures: the time between prescription
refills from the perspective of time gaps (periods of non-
adherence) or consumption (medication availability, the days of
supply/days between refills).
Electronic monitoring
Electronicmonitoring devices use an embeddedmicroprocessor to
record the time and date a person opens a medication box. Health
workers may access data from these devices by a cabled or cellular
connection. Such devices use box opening as a proxy for medica-
tion ingestion, and as such may misclassify dose-taking behaviour.
Expert opinion suggests that devices are currently unlikely to be
affordable to be used at scale in resource-limited settings, they are
likely to become much cheaper in the future (Haberer 2017).
Composite measures of the above
This describes the combination of two or more measures of adher-
ence to give a more accurate impression than a single component
can give in isolation.
Clinical pathway
Under current national and international guidelines, when a per-
son is diagnosed with HIV and linked to care, they are offered
ART. After initiation of ART, people attend for clinical review.
Clinicians may offer people more frequent clinical reviews in the
months following initiation or during intercurrent illness, and less
frequent clinical reviews once a person is established on and re-
sponding to therapy. Local guidelines and resources may also in-
fluence the frequency with which clinicians offer reviews. When
people present for these reviews clinicians may apply the index test
(measures of adherence).
At these reviews, people may also receive viral load monitoring.
This is the WHO ‘gold standard’ for confirmation of treatment
response. However, theWHO also advises that viral loadmonitor-
ing is the ‘gold standard’ for monitoring adherence (WHO 2016).
Indeed, most elevated viral loads are the result of poor adherence
(Bonner 2013). However, the relationship between adherence and
viral load is not linear. Other patient and drug-related factors will
influence viral suppression including drug resistance, viral load at
outset of therapy, history of suppression, pharmacokinetics such
as absorption, the genetic barrier to resistance offered by the regi-
men, and drug-drug interactions, as illustrated in Figure 1.
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Figure 1. Patient and drug-related factors that influence viral suppression. LLOD: lower limit of detection;
RNA: ribonucleic acid.
The frequency with which providers offer viral load monitoring,
and how the results are acted upon, will vary depending on re-
source availability. In resource-limited settings, viral loadmeasure-
ment is recommended initially at six months and then routinely
12 monthly thereafter if suppressed (WHO 2016). In more re-
source-rich settings, viral load monitoring is more frequent, sev-
eral early viral load measurements may be conducted during the
first fewmonths of ART, and routine monitoring is recommended
every three to six months. Figure 2 demonstrates simplified clini-
cal pathways as described across current guidelines.
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Figure 2. Simplified clinical pathways described in current guidelines. ART: antiretroviral therapy; LLOD:
lower limit of detection; PLHIV: people living with HIV; VL: viral load; WHO: World Health Organization.
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Prior test(s)
There are no prior tests that occur before the index test. However,
elevated viral load measurements at previous visits and clinical
findings may influence the decision to use measures of adherence.
People may receive the index test (measures of adherence) more
frequently when they have evidence of complications from HIV.
There are no differences according to age or gender.
Role of index test(s)
The index tests are already in current clinical use, and used variably
across the clinical pathways. If we could better understand which
of the available index tests are effective in detection of viral non-
suppression, this test could replace the other tests within a given
strategy. Another potential role may be as a triage test, to enable
more targeted viral load testing.
Alternative test(s)
Other purported measures of adherence that feature within the
literature include:
• directly observed therapy (DOTs): DOTs often
categorized as a ‘direct’ measure of adherence. A systematic
review of DOTS showed no benefit to viral suppression of
directly observed versus self-administered antiretroviral drugs
(Ford 2009). We will exclude this because it does not represent
‘simple triage’, and there is overlap with adherence intervention;
• therapeutic drug monitoring (TDM): the absence of a
drug with a long half-life gives objective evidence of recent non-
adherence. We will exclude this as it is resource intensive, and
generally does not give information about longer-term
adherence. Other potential caveats include that serum drug levels
may not reflect intracellular concentrations, therapeutic
thresholds are unclear, and there is great inter- and intrapatient
variability (DHHS 2017);
• pharmacological measures to quantify cumulative drug
exposure: in response to the short-term nature of the
information given by TDM, new measures are being evaluated
to reflect drug intake and metabolism over a period of weeks to
months. These include dried blood spot testing and hair testing
(Castillo-Mancilla 2018). Dried blood spot testing has not yet
been evaluated in relation to clinical outcomes in HIV treatment
and requires deep freeze within the laboratory, which is unlikely
to be viable in resource-limited settings. Hair sampling requires a
person to have and be willing to part with hair, requires
specialised laboratory services for processing, and is thus not
likely to constitute ‘simple triage’. Both these tests have future
potential;
• provider clinical judgement: a small number of studies
have investigated provider’s subjective opinions on the likely
adherence behaviour of their patient (Bangsberg 2001; Gross
2002). These represent complex qualitative assessments and are
poorly amenable to meta-analysis. Therefore, we will exclude
them from this review.
• tablet identification tests: the provider asks the patient to
identify the tablets they have been prescribed from a selection of
images of tablets (Parienti 2001). We will exclude these from this
review because these test a patient’s knowledge rather than
implementation behaviour.
Adherence research has classified measures of adherence as objec-
tive and subjective, and direct and indirect. Although such terms
appear in the literature, there is no formal taxonomy, and differ-
ent authors may use the same term to describe different measures.
Furthermore, the validity of applying these terms to HIV adher-
ence research is questionable (Williams 2013). Therefore, we will
avoid such terminology in this report.
Downstream impact of index test
The possible downstream consequences according to the four test
accuracy categories, are as follows:
• true positive: the clinician can perform additional tests (a
viral load test, an increased frequency of viral load testing in
future), or refer for an effective intervention (adherence support),
or both;
• true negative: the clinician can continue the normal viral
load testing schedule according to local practice;
• false positive: the clinician may unnecessarily perform an
additional test (viral load) or refer for an intervention (adherence
support), or both. The blood test may cause the patient distress.
The intervention may inconvenience the patient. Both test and
intervention incur costs for the provider;
• false negative: the patient will continue to receive the
normal viral load testing schedule according to local practice.
The patient has viral non-suppression which has not been
detected at that clinical review. This may lead to the
consequences of transmission of HIV to other people,
progression of HIV and the resultant morbidity and mortality, or
development of drug resistance.
Rationale
Although viral load testing is the reference standard measurement
of treatment response, it is not universally available. In resource-
limited settings, viral load testingmay either not be available or not
feasible at a high frequency. In this context, WHO has identified
a need to identify through simple triage those patients in greatest
need of adherence support. This review will seek to recommend
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measures of antiretroviral adherence which could be used in re-
source-limited settings, and determine gaps in the current body of
knowledge to inform future research.
O B J E C T I V E S
To determine the accuracy of simple measures of adherence, in-
cluding patient self-report, tablet counts, pharmacy records, elec-
tronic monitoring, or composite methods, for detecting non-sup-
pressed viral load in people living with HIV.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Inclusion criteria
• The study assesses index test(s) of interest (measures of
adherence), at the time of a viral load measurement. We
anticipate that most included studies will be conducted at a
single time point. If studies are conducted at multiple time
points, we will include them if we are able to extract data from
one or more specific time points, rather than aggregate or
longitudinal scoring.
• The study reports data comparing the index test(s) of
interest to viral load non-suppression, from which we could
extract true positive, true negative, false positive, and false
negative values.
• The study measures viral load using laboratory-based
testing platforms.
Wewill also include studieswhichmakewithin-study comparisons
of the index test(s) of interest, but will not restrict inclusion only
to such studies as we anticipate few such studies exist.
Exclusion criteria
• The study does not report the lower limit of detection of
the viral load assay used.
• The study uses a viral load assay with a lower limit of
detection greater than 400 copies per millilitre.
◦ This is because most current laboratory assays have a
lower limit of detection of less than 400 copies per millilitre, and
there is greater clarity across literature that viral loads of less than
400 copies per millilitre reflect suppression.
• Studies using non-nucleic acid testing approaches.
◦ An example of a non-nucleic acid approach is
measurement of HIV reverse transcriptase activity, this is a
surrogate for HIV viral load measurement, but is not the
reference standard.
• Studies using point-of-care tests.
We will exclude retrospective studies or case-control study designs.
These are more likely to be subject to bias, in particular in relation
to flow and timing: we anticipate that we will not be able to
confirm that the timingof the adherencemeasure and the viral load
are simultaneous, or that all patients receiving a given adherence
measure will also receive a viral load.
There will be no restrictions onminimal quality standard,minimal
sample sizes, or number of cases with viral non-suppression.
Participants
We will include studies that recruit HIV-positive adults, adoles-
cents, and children who have been established on ART for longer
than six months at the time of assessment.
Index tests
The index test will be measures of adherence that could be utilised
in resource-limited settings, and will include:
• self-report;
• tablet counts;
• pharmacy records /or secondary database analysis, or both;
• electronic monitoring;
• composite measures of the above.
Wewill categorize and analyse studies according to the above head-
ings.
There are no specific consensus criteria for identifying adherence
versus non-adherence. Studies may report different dichotomized
thresholds between ‘non-adherent’ and ‘adherent’ in relation to
measures of adherence that report implementation of a dosing
regimen over a defined interval of time. For example:
• self-report: count- or estimate-based measures of percentage
adherence over a given period;
• tablet counts: adherence percentage based on expected
versus actual tablets taken over dispensing period;
• pharmacy records or secondary database analysis, or both:
MPR;
• electronic monitoring: percent of doses received as
measured;
• composite measures of the above given a pooled percentage
estimate.
All these measures estimate a percentage of time during which a
patient takes the medication as prescribed. Typically, these studies
will then dichotomize ‘adherence’ and ‘non-adherence’, based on
a percentage threshold.
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Our definitions for the four test accuracy categories are as follows:
• true positive: the index test correctly identifies non-
adherence to ART, and as such, detects a non-suppressed viral
load;
• true negative: the index test correctly identifies adherence to
ART, and as such, detects a suppressed viral load;
• false positive: the index test misclassifies a person as non-
adherent to ART, and fails to detect a suppressed viral load;
• false negative: the index test misclassifies a person as
adherent to ART, and fails to detect a non-suppressed viral load.
Target conditions
The target condition is viral non-suppression. We will define this
as an HIV RNA level above the lower limit of detection of the
assay used within the study in question.
Reference standards
We will use a reference standard of non-suppressed viral load, as
detected using nucleic acid testing technologies. This will be any
viral load which is above the lower limit of detection of the avail-
able assay. This varies between assays, ranging from 10 copies per
millilitre to 400 copies per millilitre in those which are currently
available.
Search methods for identification of studies
The Cochrane Infectious Diseases Group Information specialists
will perform a comprehensive search to identify all relevant stud-
ies regardless of language or publication status (published, unpub-
lished, in press, and ongoing).
Electronic searches
We will search the following databases from 2003 onwards, as
these reflect more current ART regimens and viral load thresholds
(WHO 2003).
• Cochrane Central Register of Controlled Trials
(CENTRAL; the Cochrane Library);
• MEDLINE (PubMed);
• Embase (Ovid);
• Latin American and Caribbean Health Sciences Literature
(LILACS);
• CINAHL (EBSCOhost);
• Africa-Wide Information (EBSCOhost); and
• Web of Science (Core Collection (Clarivate Analytics)).
The preliminary search strategy for MEDLINE (PubMed) is pre-
sented in Appendix 1. We will adapt it for the other electronic
databases, and report all search strategies in full in the final version
of the review.
Searching other resources
To identify additional published, unpublished, and ongoing stud-
ies, we will perform the following tasks:
• screen reference lists of included studies and relevant review;
• screen the following conferences from 2016 onwards:
International AIDS Society (IAS) conferences: International
AIDS Conference, Conference on HIV Science (
www.iasociety.org/Conferences), European AIDS Conference (
www.eacsociety.org), International Conference on HIV
Treatment and Prevention Adherence ( www.iedea.org);
• search the WHO portal for any registered trials;
• contact authors who have published more than once as first
or senior author on included studies; and
• handsearch WHO reports on adherence measures.
Data collection and analysis
Selection of studies
Two review authors (PH and RH) will independently scrutinise
titles and abstracts identified from our electronic search to iden-
tify those which may be eligible. We will retrieve the full-text ar-
ticle of any citation either review author (PH or RH) identifies as
potentially eligible. Each review author will independently assess
each full-text article for inclusion. We will settle any discrepancies
via discussion between review authors, and if further uncertainty
remains, consultation with a third review author (IEW). We will
name studies according to the surname of the first author and year
of publication.
Data extraction and management
Two review authors (PH and RH) will independently extract data
using a predefined data extraction tool. We will pilot the form on
two studies from each adherence measure subtype, and finalise the
form thereafter. We will extract data on the following characteris-
tics.
• Author, publication year, study design (as defined by review
author).
• Country of study and country income status (low-income,
lower middle-income, upper middle-income, high-income), as
defined by The World Bank atlas method at the time of data
extraction (World Bank 2018).
• Age and gender of included participants.
• HIV viral load assay used.
• Type of adherence assessment used, alone or as a composite
measure, including:
◦ for self-report: number of questions, modality (self-
completion, interviewer administered), question content
(behavioural or attitudinal);
◦ for pharmacy data: MPR or tablet pick up.
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• Threshold used within the study for definition of
dichotomization of optimal and suboptimal adherence.
• QUADAS-2 items (as detailed in Appendix 2)
Two review authors (PH and RH) will then extract results and
cross-tabulate data in two-by-two tables, using the following def-
initions.
• Disease positive: people with a viral load above the lower
limit of detection used in the study assay.
• Disease negative: people with an undetectable viral load
using the study assay.
• Test positive: people defined as non-adherent within the
study, based on dichotomised percentage adherence, using a
threshold defined by the study authors.
• Test positive: people defined as adherent within the study,
based on dichotomised percentage adherence, using a threshold
defined by the study authors.
Assessment of methodological quality
We will use the QUADAS-2 tool to appraise risk of bias and ap-
plicability (Whiting 2011). This includes four domains: patient
selection, index test, reference standard, and flow and timing. To
tailor the tool for our review, we will add or omit signalling ques-
tions for each of the four domains. We have proposed an initial
schema for operating the QUADAS-2 tool in Appendix 2. Two
review authors (PH and RH) will independently pilot the form
with two studies from each adherence measure subtype, and fi-
nalise the form thereafter.
Statistical analysis and data synthesis
For all included studies, we will use the data in the two-by-two
tables (the binary test results cross-tabulated with the binary ref-
erence standard) to calculate sensitivities and specificities, along
with their 95% confidence intervals.
We will present individual study results graphically by plotting
estimates of sensitivities and specificities in a forest plot and in
receiver operating characteristic (ROC) space. This will facilitate
visual assessment of variation in test accuracy. We will use Review
Manager 5 for these descriptive analyses and to produce summary
ROC curves (Review Manager 2014).
We will perform meta-analysis for each index test. We anticipate
that there is likely to be variation in thresholds between included
studies, and this may be explicit or implicit (Leeflang 2008). Ex-
plicit variation may occur when different studies use different per-
centage adherence thresholds within the same test to define non-
adherence. There may also be implicit variation, when the test re-
sult depends on an element of interpretative judgement, especially
in the case of self-report. Given the anticipated explicit and im-
plicit variation, we will use the hierarchical summary ROCmodel
(HSROC) to pool data (sensitivities and specificities) and to plot
a summary ROC (SROC) curve for each index test. The HSROC
model estimates the underlying ROC curve, and thus describes
how sensitivity and specificity of the included studies trade off
with each other as thresholds vary.
If we encounter a sufficient number of studies that report a com-
mon threshold for adherence and non-adherence, we will use the
bivariate model, and give the estimate of the summary operating
point.
If a study reports more than one threshold, we will use the thresh-
old from the study that is most commonly reported across studies
in the meta-analysis.
We will perform meta-analysis using the NLMIXED procedure
within the MetaDAS macro for SAS (Takwoingi 2010).
Comparing index tests
In the first instance, we will make simple separate comparisons of
summary estimates from alternative index tests.
If we encounter a sufficient number of studies that make within-
study paired comparisons of the index tests of interest, we will
present linkedROCplots, inwhich the two estimates are joined by
a line. This will facilitate visual assessment of change in accuracy
within study between the tests. We will perform HSROC analysis
restricted to such studies, and compare index tests using type of
index test as a covariate within theHSROCmodel. This will allow
us to explore heterogeneity in test positivity (threshold), position
of the curve (accuracy), and shape of the curve. This would be the
preferred method of analysis, but we anticipate that we may not
find such studies.
In the absence of a sufficient number of studies making within-
study comparisons, we will make comparisons across index tests,
again using type of index test as a covariate within the HSROC
model.
Investigations of heterogeneity
For each index test, wewill formally investigate potential sources of
heterogeneity, by incorporating covariates to a hierarchical model
in our meta-analysis.
• Setting, including income status:
◦ this will include World Bank income categories: low-
income, lower- to middle-income, upper- to middle-income, and
high-income economies.
• Target population in study, as represented by child,
adolescent, or adult.
• Lower limit of detection of viral load threshold used within
the study.
• Subtype of adherence measure (e.g. by number and content
of questions within self-report adherence measures).
Where we use the HSROC model due to variation in thresholds,
we will assess the effect of covariates on the accuracy, threshold,
and shape parameters. Where we use the bivariate model, we will
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assess interaction of covariates with sensitivity or specificity, or
both.
These potential sources of heterogeneity are speculative. We pro-
pose setting and target population as potential sources given that
there are considerable differences in adherence rate between coun-
tries, and ages globally. As, to our knowledge, this is the first sys-
tematic review in this area, the relevance of these factors is yet to
be ascertained.
Sensitivity analyses
For each index test, we will conduct sensitivity analyses in which
we exclude studies for which the QUADAS-2 tool indicates areas
of methodological concern.We will exclude studies in which more
than four of our six QUADAS-2 domains are high risk. We also
plan to assess the impact of risk of bias in relation to conduct and
patient flow, and the impact of applicability in terms of whether
the measure is likely to be applicable to a resource-limited setting.
Assessment of reporting bias
We will not carry out formal assessment of publication bias be-
cause there is a lack of sensitive and appropriate statistical methods
relevant to this review methodology.
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A D D I T I O N A L T A B L E S
Table 1. Guidelines for determining viral failure
Guideline Threshold
DHHS 2017 Persistent (> 1 reading of > 200 copies/mL) denotes viral failure after 24 weeks on an ARV regimen in a person who
has not yet had documented virological suppression on this regimen
EACS 2017 Confirmed (< 1 month) HIV-VL > 50 copies/mL 6 months after starting therapy (initiation or modification) in
people on ART. Depending on the HIV-VL assay, this limit could be higher or lower
WHO 2016 Persistently detectable viral load exceeding 1000 copies/mL (i.e. 2 consecutive viral load measurements within a 3-
month interval with adherence support between measurements) after ≥ 6 months of starting a new ART regimen
ARV: antiretroviral therapy; HIV-VL: HIV viral load.
Table 2. Health service nomenclature
Tier Highest cadre Terms often used Facility and staff Equipment facilities
Community Individual with maxi-
mum of few months
training, paid or unpaid
Family-led care Family member HIV tests, counselling,
replenish drugs
Community volunteer Trained volunteer;
health assistants
Primary care clinic Nurse aide or commu-
nity health workers
Health centre Clinical officer or nurse
(≥ 2 years’ training)
Health centres; district
hospitals
Purpose built with ≥ 1
paramedic or nurse with
some health assistants
HIV tests; antiretrovi-
ral drugs; opportunis-
tic infections medicines;
point-of-care laborato-
ries
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Table 2. Health service nomenclature (Continued)
Health centre
(enhanced)
Clinical officer or nurse
(≥ 2 years’ training)
Health centres, primary
health care clinics, dis-
trict hospitals
Purpose built with ≥ 1
paramedic or nurse with
some health assistants,
with input from a doctor
(may be via mobile sup-
port service)
HIV tests; antiretrovi-
ral drugs; opportunis-
tic infections medicines;
point-of-care laborato-
ries
Hospital Doctor Health centres; district
hospitals
Purpose built with ≥
1 medical doctor with
nurses/paramedics and
assistants
CD4 count; medicines;
not viral load
Hospital (advanced) Specialist doctor District hospital; referral
hospital
Purpose built with ≥
2 specialist doctors with
nurses/paramedics and
assistants
Viral load; full investiga-
tions
A P P E N D I C E S
Appendix 1. MEDLINE (PubMed) search strategy
#1 Search All Fields (HIV OR hiv-1 OR hiv-2* OR hiv1 OR hiv2 OR hiv infect* OR human immunodeficiency virus OR human
immune deficiency virus OR human immuno-deficiency virus OR human immune-deficiency virus OR ((human immun*) AND
(deficiency virus)) OR acquired immunodeficiency syndromes OR acquired immune deficiency syndrome OR acquired immuno-
deficiency syndrome OR acquired immune-deficiency syndrome OR ((acquired immun*) AND (deficiency syndrome)) OR HIV/
AIDS)
#2 Search (HIV infections [MeSH] OR HIV [MeSH])
#3 (#1 OR #2)
#4 Search All Fields (Antiretroviral* OR ((anti) AND (retroviral*)) OR ARV* OR ART OR “antiretroviral therapy” OR HAART OR
((highly) AND (active) AND (antiretroviral*) AND (therap*)) OR ((anti) AND (hiv)) OR ((anti) AND (acquired immunodeficiency))
OR ((anti) AND (acquired immuno-deficiency)) OR ((anti) AND (acquired immune-deficiency)) OR ((anti) AND (acquired immun*)
AND (deficienc*)))
#5 Search (antiretroviral agents [Mesh] OR antiretroviral therapy, highly active [Mesh])
#6 (#4 OR #5)
#7 (#3 AND #6)
#8 Search All Fields (adhereOR adherenceOR adheredOR adheresORnonadherence ORnon-adherence OR compliesOR complying
OR comply OR compliance OR concordance OR patient dropouts OR treatment dropouts OR treatment refusal OR “pill counts”
OR “pill counting” OR “pill count” OR “pharmacy records” OR “pharmacy recording” OR “drug counting” OR “drug counts” OR
“drug count” OR dispensed OR dispensary OR “pharmacy recorded” OR “pharmacy-recorded”)
#9 Search ((“Patient Dropouts”[Mesh]) OR (“Patient Compliance”[Mesh]) OR (“Treatment Adherence and Compliance”[Mesh]) OR
(“Medication Adherence”[Mesh]))
#10 (#8 OR #9)
#11 Search All Fields (viral non-suppression OR viral suppression OR viral load OR virologic outcome* OR low level viraemia OR
low level viremia OR viral blips OR viral failure OR viral rebound OR incomplete viral response)
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#12 Search ((“Viral Load”[Mesh]) OR (“Sustained Virologic Response”[Mesh]))
#13 (#11 OR #12)
#14 Search (animals [Mesh] NOT humans [Mesh])
#15 (#7 AND #10 AND #13)
#16 (#15 NOT #14)
#17 Sort by: Best Match Filters: Publication date from 1996/01/01
Appendix 2. QUADAS-2: list of signalling questions, risk of bias, and applicability
Domain Patient selection Index test Reference standard Flow and timing
Description We will describe meth-
ods of patient selection,
and the intended use of
the adherencemeasure in
this setting
We will describe the
measure of adherence,
and how the researchers
interpreted it
We will describe the
method used to measure
viral load and the lower
limit of detection of the
assay
We will describe any in-
terval between the adher-
ence measure and the vi-
ral load measurement
Signalling questions
(yes, no, unclear)
Consecutive or random
sample of patients?
Yes: if authors stated
they used random pa-
tient sampling or consec-
utive enrolment
No: when patients were
selected, for
example, based on previ-
ously identified concerns
regarding adherence
Unclear: if authors pro-
vided insufficient infor-
mation.
Index test results inter-
preted without knowl-
edge of the results of ref-
erence standard?
Yes: if authors clearly re-
ported that the measures
of adherence were ap-
plied and interpreted be-
fore the viral load result
was available
No: if authors reported
that the measures were
applied or interpreted af-
ter the viral load was
available
Unclear: if authors pro-
vided insufficient infor-
mation.
Reference
standard likely to cor-
rectly classify the target
condition?
Yes: if authors clearly
reported that a labora-
tory reference test was
used at a manufacturer
recommended threshold
of lower limit of detec-
tion, and this was < 400
copies/mL
No: if authors reported
application of a post-hoc
threshold.
Unclear: if authors pro-
vided insufficient infor-
mation.
Appropriate in-
terval between measure
of adherence and viral
load measurement?
Yes: if the measure of ad-
herence and the measure
of viral load were made
on the same day
No: if time period be-
tween measure of adher-
ence and viral load was
not made on the same
day
Unclear: if authors pro-
vided insufficient infor-
mation.
Did the study avoid in-
appropriate exclusions?
Yes: if there were no in-
appropriate exclusions.
No: if there was evi-
dence that authors inap-
propriately excluded cer-
tain patients, e.g. those
deemed to have limited
ability to use electronic
monitoring devices, or
excluded those with lit-
eracy concerns if self-re-
Prespecified threshold
used?
Yes: if authors reported
an a priori threshold
value (or values) for ad-
herence
No: if authors deter-
mined threshold values
post hoc.
Unclear: if authors pro-
vided insufficient infor-
mation.
Reference standard re-
sults interpreted with-
out knowledge of the in-
dex test?
Yes: if authors reported
that viral loadsweremea-
sured and recorded with-
out a priori knowledge of
themeasure of adherence
result
No: if authors reported
that viral load was mea-
Did all patients receive
a viral load, using the
sameassay, andwere all
included in the analy-
sis?
Yes: if authors reported
that all patients received
a viral load using the
same assay and all were
included in the analysis
No: if only a selection
of those with adherence
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(Continued)
port measures were to be
self-administered
Unclear: if authors pro-
vided insufficient infor-
mation.
sured or recorded with
knowledge of the mea-
sure of adherence result
Unclear: if authors pro-
vided insufficient infor-
mation.
measures have viral load
measures, or different as-
says were used
Unclear: if authors pro-
vided insufficient infor-
mation.
Risk of bias (high, low,
unclear)
• If we answer both signalling questions for a domain ‘yes’, then we will judge risk of bias as low.
• If we answer both signalling questions for a domain ‘no’, then we will judge risk of bias as high.
• If we answer both signalling questions for a domain ‘unclear’, then we will judge the risk of bias as
unclear.
• If we answer both signalling questions for a domain differently, the authors will discuss this further
to reach a final judgement, and explain the rationale for this judgement within the ‘Risk of bias’ table.
Applicability concerns
(high, low, unclear)
Are there concerns that
the included patients do
not match the review
question?
High: if some but not all
included patients were
concurrently receiving
interventions to improve
their adherence, rather
than the same standard
of care, and these groups
cannot be separated
Low: if all patients were
receiving the same stan-
dard of care.
Unclear: if there was in-
sufficient information to
make a judgement.
Are there concerns that
the index test, its con-
duct, or interpretation
differs from the review
question?
High: if the measure
of adherence was not
truly applicable in a re-
source-limited setting, e.
g. requiring additional
remote information in-
frastructure or analysis
Low: if the measure of
adherence could feasibly
be applied in a resource-
limited setting
Unclear: if there was in-
sufficient information to
make a judgement.
- -
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